Optical Brightening Agent BBU-480 | CAS:16470-24-9

We serve Optical Brightening Agent BBU-480 CAS:16470-24-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Optical Brightening Agent BBU-480

Optical Brightening Agent BBU-480
 
Main composition
C.I.No:220
CAS No:16470-24-9
Molecular mass:1165.04
Formula:C40H40N12O16S4Na4
Type of product:Mixture substance
 
Technical index  
Appearance:Yellowish granule
pH Value:6.0~8.0
Ionic character:anion
 
Performance and Features  
1.Convenient in application, suitable for continuous addition。
2.Good fluorescent whitening performance in the pulp, surface sizing and coating processes.
 
Application Methods:
1.During coating, it can be added in any process. It has better performance with the carrier of CMC, PVA and starch. Usual dosage: 0.05~0.4% based on dry pigment.
2.During surface sizing, it has better performance with the carriers of CMC, PVA and starch. Usual dosage: 0.1~3g/L.
3.It can be directly added into the pulp, when being added, should avoid adding together with the other cationic chemicals or directly contact, mix. Adding in the pulp, the proportion based on weight of between OBA and absolutely dry pulp is 0.01~0.4%.
 
Packaging and Storage  
Packaging with 25kg bag or special packaging according to customers, more than two years of stability，store at the place with room temperature.



Contact us for information like Optical Brightening Agent BBU-480 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Optical Brightening Agent BBU-480 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Optical Brightening Agent BBU-480 Use and application,Optical Brightening Agent BBU-480 technical grade,usp/ep/jp grade.


Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.Ethyl linoleate (JAN) manufacturer The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butane-1,3-dione supplier The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.Ribonucleic acid vendor This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.